loader
Please Wait
Applying Filters...

Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of Certificates of Suitability (CEPs) for cep_2021_466___rev_01 Active Pharmaceutical Ingredient (API) issued by the EDQM. Original Data: EDQM Database

    Client Virtual Booth
    Menu

    Srini Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    INTERMEDIATES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Send me more info on How To Grow My Business Digitally?

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 SRINI PHARMACEUTICALS PRIVATE LIMITED Choutuppal IN (1)

    filter

    01 Rivaroxaban (1)

    filter

    01 India (1)

    filter

    01 Valid (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us

    SRINI PHARMACEUTICALS PRIVATE LIMIT...

    Contact Supplier
    • FDA
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Rivaroxaban

    PDF Supplier PDF
    URL Supplier Web Content
    CEP 2021-466 - Rev 01
    Valid
    Chemical
    2023-09-14
    2932
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    Looking for Certificates of Suitability (CEPs) for CEP 2021-466 - Rev 01 of Srini Pharmaceuticals Private Limited Choutuppal In

    Looking for Certificates of Suitability (CEPs) for CEP 2021-466 - Rev 01 of Srini Pharmaceuticals Private Limited Choutuppal In 1

    20

    Srini Pharmaceuticals Private Limited Choutuppal In, based in India, is a pharmaceutical company that stands out with its certifications from FDA.

    One of their significant offerings is Rivaroxaban, supported by a 'Valid' Certificate of Suitability (CEP) with the number CEP 2021-466 - Rev 01

    This Chemical Type CEP, issued on September 14, 2023, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.

    Substance Number 2932 associated with this CEP further emphasizes

    Post Enquiry
    POST ENQUIRY